-
12316 - Alavi
Spesolimab for hidradenitis suppurativa: A proof-of-concept study
Afsaneh Alavi, Errol Prens, Alexa B. Kimball, James G. Krueger, Sutirtha Mukhopadhyay, Hui Wang, Nathalie B. Ivanoff, Ana C. Hernandez Daly, Christos C. Zouboulis
-
12318 - Armstrong
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: Correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
April W. Armstrong, Kim A. Papp, Joe Zhuo, Brandon Becker, Yichen Zhong, Jennifer L. Beaumont, Michael DeRosa, Renata M. Kisa, Subhashis Banerjee, Bruce Strober
-
12319 - Armstrong
Assessing humanistic burden in patients with moderate to severe psoriasis in the United States
April W. Armstrong; Lauren Seigel; Sayeli Jayade; Sanika Rege; Hannah Penton; Vardhaman Patel; David Davidson; Samaneh Kalirai; Daniel Wolin; Kimberly Boyle; Tina Bhutani
-
12320 - Armstrong
Optimizing the Treatment Sequence: The Cumulative Clinical Benefit of Treatment Initiation With Deucravacitinib Versus Apremilast Over 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis From the POETYK PSO-1 trial
April W. Armstrong; Sang Hee Park; Viktor Chirikov; Pierre Nicolas; Wei-Jhih Wang; Matthew J. Colombo; Vardhaman Patel
-
12321 - Armstrong
Optimizing the treatment sequence: The cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial
April W. Armstrong; Sang Hee Park; Viktor Chirikov; Pierre Nicolas; Wei-Jhih Wang; Matthew J. Colombo; Vardhaman Patel
-
12322 - Armstrong
Barriers to Accessing Treatment for Plaque Psoriasis: A National Psoriasis Foundation Survey
April W. Armstrong, Tina Bhutani, Douglas DiRuggiero, Stephanie Simmerman, Kirk Gautier, Doral Fredericks, Anna M. Tallman
-
12323 - Armstrong
Assessing Imputation Methods With the Lebrikizumab Clinical Trial Program
April W. Armstrong, Jonathan I. Silverberg, Jacob P. Thyssen, Richard B. Warren, Alan D. Irvine, Eric Wolf, Yuxin Ding, Yong Lin, Sarah Reifeis, Mertixell Falques, Eric Simpson
-
12324 - Armstrong
Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis
April W. Armstrong, Robert Bissonnette, Philip M. Brown, Anna M. Tallman, Kim A. Papp
-
12325 - Armstrong
Quality of Life and Mental Health of Patients Stratified by Prior Biologic Exposure: Post hoc Analysis of Brodalumab
April Armstrong, Brad Glick, Tina Bhutani, Abby Jacobson
-
12326 - Bagel
Real-world effectiveness of dupilumab in atopic dermatitis: Consistency in rate and magnitude of improvement across observational study methodologies
Jerry Bagel, Tien Q. Nguyen, Eric Simpson, Hermenio Lima, Dimittri Delevry, Chien-Chia Chuang, Debra Sierka, Moataz Daoud, Andrew Korotzer
-
12328 - Baldwin
Re-Formulating the Old Tretinoin: Unique Microencapsulated Tretinoin with Microencapsulated Benzoyl Peroxide Combination Product for Acne Vulgaris
Hilary Baldwin, MD; Omar Noor, MD; Mark. Jackson, MD; Guy Webster, MD; Maya Erlich, PhD; Krysten Arekapudi, DNP; James J. Leyden, MD
-
12327 - Baldwin
EVOLUTION OF BENZOYL PEROXIDE: MICROENCAPSULATED 5% CREAM TO IMPROVE TOLERABILITY IN PAPULOPUSTULAR ROSACEA
Hilary Baldwin, MD; Boni Elewski, MD; Ofra Levy-Hacham, MD; Firas Hougier, MD; Paul Yamauchi, MD, PhD; Kate Hamil, PharmD; JP York, PhD; Julie Harper, MD
-
12329 - Bhatia
Real-world effectiveness and safety in a Phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Neal Bhatia, J Gabriel Vasquez, Brad Schenkel, Ranga Gogineni, Jayme Heim
-
12330 - Bhatia
Psoriasis-related work productivity improvement from a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Neal Bhatia, Jayme Heim, Brad Schenkel, Ranga Gogineni, J Gabriel Vasquez
-
12331 - Bissonnette
Rapid, substantial, and sustained reduction of itch in adults with atopic dermatitis applying ruxolitinib cream
Robert Bissonnette, MD, FRCPC, Haobo Ren, PhD, Haq Nawaz, MD, MPH, MBA, MS, Philippa Halden, MSc, Etienne Saint-Cyr Proulx, MD, FRCPC
-
12334 - Blauvelt
Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus
Andrew Blauvelt, Zoe D. Draelos, Melinda Gooderham, Edward Lain, Angela Y. Moore, Kim A. Papp, Matthew Zirwas, David Krupa, Patrick Burnett, David R. Berk, David H. Chu
-
12335 - Blauvelt
Ruxolitinib Cream Monotherapy Use Demonstrates Maintenance of Disease and Symptom Control With Use As Needed in Adults and Adolescents With Atopic Dermatitis: Pooled Analysis From the Long Term Safety Periods of Two Phase 3 Studies
Andrew Blauvelt, MD, MBA, Leon Kircik, MD, Eric L. Simpson, MD, MCR, Peter Lio, MD, Daniel Sturm, PharmD, Howard Kallender, PhD, Haobo Ren, PhD, Dilan Paranagama, PhD, Jessy Gao, MA, Lawrence F. Eichenfield, MD
-
12332 - Blauvelt
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis: Subgroup Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F. Merola, Mark Lebwohl, Thomas Scharnitz, Kim Hoyt, Renata M. Kisa, Subhashis Banerjee, Alexandra B. Kimball
-
12336 - Bouaziz
Efficacy of nemolizumab in atopic dermatitis: Rapid impact on EASI and SCORAD components
Jean-David Bouaziz, MD, PhD; Andreas Pinter, MD; Afsaneh Alavi, MD; Sandy Alpizar, MD; Grayzna Pulka, MD, PhD; Faiz Ahmad, MS; Kamel Chaouche, MD; Warren Winkelman, MD; Christophe Piketty, MD, PhD
-
12338 - Cheng
A case of accessory breast in an adolescent female
Melissa Cheng, Christopher Wong DO, Michael Carletti DO, Stephen E. Weis DO